New developments in anti-sickling agents: can drugs directly prevent the polymerization of sickle haemoglobin in vivo?

British Journal of Haematology

Volumn 175, Issue 1, 2016, Pages 24-30

  Oder, Esther ^a   Safo, Martin K ^b   Abdulmalik, Osheiza ^c   Kato, Gregory J ^d  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

5 hydroxymethylfurfural; anti sickling; GBT440; haemoglobin allosteric effectors; sickle cell; TD 1; vanillin

Indexed keywords

5 HYDROXYMETHYLFURFURAL; ALDEHYDE; ANTIANEMIC AGENT; DI [5 (2,3 DIHYDRO 1,4 BENZODIOXIN 2 YL) 4H 1,2,4 TRIAZOL 3 YL]DISULFIDE; GBT 440; HEMOGLOBIN; INN 312; UNCLASSIFIED DRUG;

ALLOSTERISM; BINDING SITE; DOSE RESPONSE; DRUG ABSORPTION; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TOLERABILITY; ERYTHROCYTE; HEMOGLOBIN DETERMINATION; HUMAN; NONHUMAN; OXYGEN AFFINITY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POINT MUTATION; PRIORITY JOURNAL; REVIEW; SICKLE CELL ANEMIA; STOICHIOMETRY;

EID: 85027941976     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.14264     Document Type: Review

References (58)

1. Abdella, P.M., Ritchey, J.M., Tam, J.W. & Klotz, I.M. (1977) Glycosylation of hemoglobin S by reducing sugars and its effect on gelation. Biochimica et Biophysica Acta, 490, 462–470.
2. Abdulmalik, O., Safo, M.K., Chen, Q., Yang, J., Brugnara, C., Ohene-Frempong, K., Abraham, D.J. & Asakura, T. (2005) 5-hydroxymethyl-2-furfural modifies intracellular sickle haemoglobin and inhibits sickling of red blood cells. British Journal of Haematology, 128, 552–561.
3. Abdulmalik, O., Ghatge, M.S., Musayev, F.N., Parikh, A., Chen, Q., Yang, J., Nnamani, I., Danso-Danquah, R., Eseonu, D.N., Asakura, T., Abraham, D.J., Venitz, J. & Safo, M.K. (2011) Crystallographic analysis of human hemoglobin elucidates the structural basis of the potent and dual antisickling activity of pyridyl derivatives of vanillin. Acta Crystallographica. Section D, Biological Crystallography, 67, 920–928.
4. Abdulmalik, O., Deshpande, T., Ghatge, M., Zhang, Y., Venitz, J., Parikh, A. & Safo, M.K. (2014) Novel structurally-modified allosteric effectors of hemoglobin exhibit superior antisickling properties. Blood, 124, 218.
5. Abraham, D.J., Mehanna, A.S., Wireko, F.C., Whitney, J., Thomas, R.P. & Orringer, E.P. (1991) Vanillin, a potential agent for the treatment of sickle cell anemia. Blood, 77, 1334–1341.
6. Arya, R., Rolan, P.E., Wootton, R., Posner, J. & Bellingham, A.J. (1996) Tucaresol increases oxygen affinity and reduces haemolysis in subjects with sickle cell anaemia. British Journal of Haematology, 93, 817–821.
7. Beddell, C.R., Goodford, P.J., Kneen, G., White, R.D., Wilkinson, S. & Wootton, R. (1984) Substituted benzaldehydes designed to increase the oxygen affinity of human haemoglobin and inhibit the sickling of sickle erythrocytes. British Journal of Pharmacology, 82, 397–407.
8. Beutler, E., Paniker, N.V. & West, C. (1971) The effect of 2,3-DPG on the sickling phenomenon. Blood, 37, 184–186.
9. Bookchin, R.M. & Gallop, P.M. (1968) Structure of hemoglobin AIc: nature of the N-terminal beta chain blocking group. Biochemical and Biophysical Research Communications, 32, 86–93.
10. Bunn, H.F. & Forget, G.B. (1986) Hemoglobin: Molecular, Genetic and Clinical Aspects, p. 462. W. B. Saunders Company, Philadelphia, PA.
11. Bunn, H.F., Haney, D.N., Gabbay, K.H. & Gallop, P.M. (1975) Further identification of the nature and linkage of the carbohydrate in hemoglobin A1c. Biochemical and Biophysical Research Communications, 67, 103–109.
12. Charache, S., Grisolia, S., Fiedler, A.J. & Hellegers, A.E. (1970) Effect of 2,3-diphosphoglycerate on oxygen affinity of blood in sickle cell anemia. The Journal of Clinical Investigation, 49, 806–812.
13. Dufu, K., Oksenberg, D., Metcalf, B. & Sinha, U. (2013) GTx011, a potent allosteric modifier of hemoglobin oxygen affinity, delays polymerization and prevents sickling. Blood, 122, 316.
14. Dufu, K., Oksenberg, D., Zhou, C., Hutchaleelaha, A. & Archer, D.R. (2014) GTx011, a potent allosteric modifier of hemoglobin oxygen afifinty, prevents RBC sickling in whole blood and prolongs RBC half-life in vivo in a murine model of sickle cell disease. Blood, 124, 217.
15. Fens, M., Larkin, S.K., Morris, C.R., Fitch, B., Scicinski, J., Oronsky, B. & Kuypers, F.A. (2011) NO or no NO, increased reduction of nitrite to nitric oxide by modified red blood cells. Blood, 118, 2125.
16. Ferrone, F.A. (2015) The delay time in sickle cell disease after 40 years: a paradigm assessed. American Journal of Hematology, 90, 438–445.
17. Fitzharris, P., McLean, A.E., Sparks, R.G., Weatherley, B.C., White, R.D. & Wootton, R. (1985) The effects in volunteers of BW12C, a compound designed to left-shift the blood-oxygen saturation curve. British Journal of Clinical Pharmacology, 19, 471–481.
18. Gibson, S., Raziee, H.R. & Lemmens, T. (2015) Why the shift? Taking a closer look at the growing interest in niche markets and personalized medicine. World Medical & Health Policy, 7, 3–27.
19. Haney, D.N. & Bunn, H.F. (1976) Glycosylation of hemoglobin in vitro: affinity labeling of hemoglobin by glucose-6-phosphate. Proceedings of the National Academy of Sciences of the United States of America, 73, 3534–3538.
20. Hannemann, A., Cytlak, U.M., Rees, D.C., Tewari, S. & Gibson, J.S. (2014) Effects of 5-hydroxymethyl-2-furfural on the volume and membrane permeability of red blood cells from patients with sickle cell disease. Journal of Physiology, 592, 4039–4049.
21. Holmquist, W.R. & Schroeder, W.A. (1966) A new N-terminal blocking group involving a Schiff base in hemoglobin AIc. Biochemistry, 5, 2489–2503.
22. Hughes, J.P., Rees, S., Kalindjian, S.B. & Philpott, K.L. (2011) Principles of early drug discovery. British Journal of Pharmacology, 162, 1239–1249.
23. Hutchaleelaha, A., Patel, M., Silva, A., Oksenberg, D. & Metcalf, B. (2015) GBT440 demonstrates high specificity for red blood cells in nonclinical species. Blood, 126, 2172.
24. Jenkins, J.D., Musayev, F.N., Danso-Danquah, R., Abraham, D.J. & Safo, M.K. (2009) Structure of relaxed-state human hemoglobin: insight into ligand uptake, transport and release. Acta Crystallographica. Section D, Biological Crystallography, 65, 41–48.
25. Jensen, F.B. (2009) The dual roles of red blood cells in tissue oxygen delivery: oxygen carriers and regulators of local blood flow. Journal of Experimental Biology, 212, 3387–3393.
26. Kato, G.J., Lawrence, M.P., Mendelsohn, L.G., Saiyed, R., Wang, X., Conrey, A.K., Starling, J.M., Grimes, G., Taylor, J.G., McKew, J., Minniti, C.P. & Stern, W. (2013) Phase 1 clinical trial of the candidate anti-sickling agent Aes-103 in adults with sickle cell anemia. Blood, 122, 1009.
27. Keidan, A.J., Franklin, I.M., White, R.D., Joy, M., Huehns, E.R. & Stuart, J. (1986) Effect of BW12C on oxygen affinity of haemoglobin in sickle-cell disease. Lancet, 1, 831–834.
28. Keidan, A.J., Sowter, M.C., Johnson, C.S., Marwah, S.S., & Stuart, J. (1989) Pharmacological modification of oxygen affinity improves deformability of deoxygenated sickle erythrocytes: a possible therapeutic approach to sickle cell disease. Clinical Science, 357–362.
29. Lehrer-Graiwer, J., Howard, J., Hemmaway, C.J., Awogbade, M., Telfer, P., Layton, M., Mant, T., Dufu, K., Hutchaleelaha, A., Koller, T., Oksenberg, D., Patel, M. & Ramos, E. (2015) GBT440, a potent anti-sickling hemoglobin modifier reduces hemolysis, improves anemia and nearly eliminates sickle cells in peripheral blood of patients with sickle cell disease. Blood, 126, 542.
30. Li, Y.X., Li, Y., Qian, Z.J., Kim, M.M. & Kim, S.K. (2009) In vitro antioxidant activity of 5-HMF isolated from marine red alga Laurencia undulata in free-radical-mediated oxidative systems. Journal of Microbiology and Biotechnology, 19, 1319–1327.
31. Li, M.M., Wu, L.Y., Zhao, T., Wu, K.W., Xiong, L., Zhu, L.L. & Fan, M. (2011a) The protective role of 5-hydroxymethyl-2-furfural (5-HMF) against acute hypobaric hypoxia. Cell Stress and Chaperones, 16, 529–537.
32. Li, M.M., Wu, L.Y., Zhao, T., Xiong, L., Huang, X., Liu, Z.H., Fan, X.L., Xiao, C.R., Gao, Y., Ma, Y.B., Chen, J.J., Zhu, L.L. & Fan, M. (2011b) The protective role of 5-HMF against hypoxic injury. Cell Stress and Chaperones, 16, 267–273.
33. MacDonald, R. (1977) Red cell 2,3-diphosphoglycerate and oxygen affinity. Anaesthesia, 32, 544–553.
34. Mendelsohn, L.G., Pedoeim, L., Wang, Y.K., Saiyed, R., Brantner, C.A., Daniels, M.P., Nichols, J.S., Wang, X., van Beers, E.J. & Kato, G.J. (2013) The anti-sickling agent Aes-103 decreases sickle erythrocyte fragility, hypoxia-induced sickling and hemolysis in vitro. Blood, 122, 940.
35. Merrett, M., Stammers, D.K., White, R.D., Wootton, R. & Kneen, G. (1986) Characterization of the binding of the anti-sickling compound, BW12C, to haemoglobin. The Biochemical Journal, 239, 387–392.
36. Nakagawa, A., Lui, F.E., Wassaf, D., Yefidoff-Freedman, R., Casalena, D., Palmer, M.A., Meadows, J., Mozzarelli, A., Ronda, L., Abdulmalik, O., Bloch, K.D., Safo, M.K. & Zapol, W.M. (2014) Identification of a small molecule that increases hemoglobin oxygen affinity and reduces SS erythrocyte sickling. ACS Chemical Biology, 9, 2318–2325.
37. Nnamani, I.N., Joshi, G.S., Danso-Danquah, R., Abdulmalik, O., Asakura, T., Abraham, D.J. & Safo, M.K. (2008) Pyridyl derivatives of benzaldehyde as potential antisickling agents. Chemistry & Biodiversity, 5, 1762–1769.
38. Omar, A.M., Mahran, M.A., Ghatge, M.S., Chowdhury, N., Bamane, F.H., El-Araby, M.E., Abdulmalik, O. & Safo, M.K. (2015) Identification of a novel class of covalent modifiers of hemoglobin as potential antisickling agents. Organic & Biomolecular Chemistry, 13, 6353–6370.
39. Patel, M., Oksenberg, D., Silva, A., Betz, A., Metcalf, B. & Sinha, U. (2013) GTx011, a novel agent that improves rheological properties of sickle cell blood by increasing oxygen affinity for hemoglobin. Blood, 122, 2207.
40. Patel, M., Cabrales, P., Dufu, K., Metcalf, B. & Sinha, U. (2014) GTx011, an anti-sickling compound, improves SS blood rheology by reduction of Hb S polymerization via allosteric modulation of O2 affinity. Blood, 124, 1370.
41. Perampaladas, K., Masum, H., Kapoor, A., Shah, R., Daar, A.S. & Singer, P.A. (2010) The road to commercialization in Africa: lessons from developing the sickle-cell drug Niprisan. BMC International Health and Human Rights, 10, S11.
42. Poillon, W.N. & Kim, B.C. (1990) 2,3-diphosphoglycerate and intracellular ph as interdependent determinants of the physiologic solubility of deoxyhemoglobin S. Blood, 76, 1028–1036.
43. Poillon, W.N., Robinson, M.D. & Kim, B.C. (1985) Deoxygenated sickle hemoglobin. Modulation of its solubility by 2,3-diphosphoglycerate and other allosteric polyanions. Journal of Biological Chemistry, 260, 13897–13900.
44. Poillon, W.N., Kim, B.C., Welty, E.V. & Walder, J.A. (1986) The effect of 2,3-diphosphoglycerate on the solubility of deoxyhemoglobin S. Archives of Biochemistry and Biophysics, 249, 301–305.
45. Riggs, A. & Wells, M. (1961) The oxygen equilibrium of sickle-cell hemoglobin. Biochimica et Biophysica Acta, 50, 243–248.
46. Rogers, S.C., Ross, J.G., d'Avignon, A., Gibbons, L.B., Gazit, V., Hassan, M.N., McLaughlin, D., Griffin, S., Neumayr, T., Debaun, M., DeBaun, M.R. & Doctor, A. (2013) Sickle hemoglobin disturbs normal coupling among erythrocyte O2 content, glycolysis, and antioxidant capacity. Blood, 121, 1651–1662.
47. Rolan, P.E., Parker, J.E., Gray, S.J., Weatherley, B.C., Ingram, J., Leavens, W., Wootton, R. & Posner, J. (1993) The pharmacokinetics, tolerability and pharmacodynamics of tucaresol (589C80; 4[2-formyl-3-hydroxyphenoxymethyl] benzoic acid), a potential anti-sickling agent, following oral administration to healthy subjects. British Journal of Clinical Pharmacology, 35, 419–425.
48. Rolan, P.E., Mercer, A.J., Wootton, R. & Posner, J. (1995) Pharmacokinetics and pharmacodynamics of tucaresol, an antisickling agent, in healthy volunteers. British Journal of Clinical Pharmacology, 39, 375–380.
49. Safo, M.K., Abdulmalik, O., Danso-Danquah, R., Burnett, J.C., Nokuri, S., Joshi, G.S., Musayev, F.N., Asakura, T. & Abraham, D.J. (2004) Structural basis for the potent antisickling effect of a novel class of five-membered heterocyclic aldehydic compounds. Journal of Medicinal Chemistry, 47, 4665–4676.
50. Safo, M.K., Ahmed, M.H., Ghatge, M.S. & Boyiri, T. (2011) Hemoglobin-ligand binding: understanding Hb function and allostery on atomic level. Biochimica et Biophysica Acta, 1814, 797–809.
51. Stern, W., Mathews, D., McKew, J., Shen, X. & Kato, G.J. (2012) A phase 1, first-in-man, dose-response study of Aes-103 (5-HMF), an anti-sickling, allosteric modifier of hemoglobin oxygen affinity in healthy normal volunteers. Blood, 120, 3210.
52. Swerdlow, P.H., Bryan, R.A., Bertles, J.F., Poillon, W.N., Hagdoff-Fairchild, B. & Milner, P.F. (1977) Effect of 2,3-diphosphoclycerate on the solubility of deoxy-sickle hemoglobin. Hemoglobin, 1, 527–537.
53. Thomas, C. & Lumb, A.B. (2012) Physiology of haemoglobin. Continuing Education in Anaesthesia, Critical Care & Pain, 12, 251–256.
54. Villela, N.R., Cabrales, P., Tsai, A.G. & Intaglietta, M. (2009) Microcirculatory effects of changing blood hemoglobin oxygen affinity during hemorrhagic shock resuscitation in an experimental model. Shock, 31, 645–652.
55. Wright, M., Sim, D., Alonso-Galicia, M., Kaalin Kauser, K. & Abe, K. (2015) Protection of microvascular liver perfusion with 5-hydroxymethylfurfural in sickle cell disease mice following hypoxia-induced vasoocclusion. Blood, 126, 2282.
56. Yalcin, O. & Cabrales, P. (2012) Increased hemoglobin O2 affinity protects during acute hypoxia. American Journal of Physiology. Heart and Circulatory Physiology, 303, H271–H281.
57. Zaugg, R.H., Walder, J.A. & Klotz, I.M. (1977) Schiff base adducts of hemoglobin. Modifications that inhibit erythrocyte sickling. Journal of Biological Chemistry, 252, 8542–8548.
58. Zhao, L., Chen, J., Su, J., Li, L., Hu, S., Li, B., Zhang, X., Xu, Z. & Chen, T. (2013) In vitro antioxidant and antiproliferative activities of 5-hydroxymethylfurfural. Journal of Agricultural and Food Chemistry, 61, 10604–10611.